SrasV1, PascalFrancis, Corpus, bibRecord, 000876

S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients

Identifieur interne : 000876 ( PascalFrancis/Corpus ); précédent : 000875; suivant : 000877

S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients

Auteurs : Heike Hofmann ; Kim Hattermann ; Andrea Marzi ; Thomas Gramberg ; Martina Geier ; Mandy Krumbiegel ; Seraphin Kuate ; Klaus Überla ; Matthias Niedrig ; Stefan Pöhlmann

Source :

Journal of virology [ 0022-538X ] ; 2004.

RBID : Pascal:04-0316775

Descripteurs français

Pascal (Inist)
- Coronavirus, Homme, Vitronectine, Protéine, Lignée cellulaire, Cellule cible, Anticorps neutralisant, Neutralisation, Infection, Microbiologie, Syndrome respiratoire aigu sévère, Carcinome hépatocellulaire, Virologie.

English descriptors

KwdEn :
- Cell line, Coronavirus, Hepatocellular carcinoma, Human, Infection, Microbiology, Neutralization, Neutralizing antibody, Protein, Severe acute respiratory syndrome, Target cell, Virology, Vitronectin.

Abstract

The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) causes severe pneumonia with a fatal outcome in approximately 10% of patients. SARS-CoV is not closely related to other coronaviruses but shares a similar genome organization. Entry of coronaviruses into target cells is mediated by the viral S protein. We functionally analyzed SARS-CoV S using pseudotyped lentiviral particles (pseudotypes). The SARS-CoV S protein was found to be expressed at the cell surface upon transient transfection. Coexpression of SARS-CoV S with human immunodeficiency virus-based reporter constructs yielded viruses that were infectious for a range of cell lines. Most notably, viral pseudotypes harboring SARS-CoV S infected hepatoma cell lines but not T- and B-cell lines. Infection of the hepatoma cell line Huh-7 was also observed with replication-competent SARS-CoV, indicating that hepatocytes might be targeted by SARS-CoV in vivo. Inhibition of vacuolar acidification impaired infection by SARS-CoV S-bearing pseudotypes, indicating that S-mediated entry requires low pH. Finally, infection by SARS-CoV S pseudotypes but not by vesicular stomatitis virus G pseudotypes was efficiently inhibited by a rabbit serum raised against SARS-CoV particles and by sera from SARS patients, demonstrating that SARS-CoV S is a target for neutralizing antibodies and that such antibodies are generated in SARS-CoV-infected patients. Our results show that viral pseudotyping can be employed for the analysis of SARS-CoV S function. Moreover, we provide evidence that SARS-CoV infection might not be limited to lung tissue and can be inhibited by the humoral immune response in infected patients.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0022-538X`
A03		`1`		`@0 J. virol.`
A05				`@2 78`
A06				`@2 12`
A08	`01`	`1`	`ENG`	`@1 S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients`
A11	`01`	`1`		`@1 HOFMANN (Heike)`
A11	`02`	`1`		`@1 HATTERMANN (Kim)`
A11	`03`	`1`		`@1 MARZI (Andrea)`
A11	`04`	`1`		`@1 GRAMBERG (Thomas)`
A11	`05`	`1`		`@1 GEIER (Martina)`
A11	`06`	`1`		`@1 KRUMBIEGEL (Mandy)`
A11	`07`	`1`		`@1 KUATE (Seraphin)`
A11	`08`	`1`		`@1 ÜBERLA (Klaus)`
A11	`09`	`1`		`@1 NIEDRIG (Matthias)`
A11	`10`	`1`		`@1 PÖHLMANN (Stefan)`
A14	`01`			`@1 Institute for Clinical and Molecular Virology, University Erlangen-Nürnberg @2 91054 Erlangen @3 DEU @Z 1 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 10 aut.`
A14	`02`			`@1 Nikolaus-Fiebiger-Center, University Erlangen-Nürnberg @2 91054 Erlangen @3 DEU @Z 1 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 10 aut.`
A14	`03`			`@1 Robert Koch Institute @2 13353 Berlin @3 DEU @Z 2 aut. @Z 9 aut.`
A14	`04`			`@1 Department for Molecular and Medical Virology, Ruhr University Bochum @2 44801 Bochum @3 DEU @Z 7 aut. @Z 8 aut.`
A20				`@1 6134-6142`
A21				`@1 2004`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 13592 @5 354000112010850060`
A44				`@0 0000 @1 © 2004 INIST-CNRS. All rights reserved.`
A45				`@0 75 ref.`
A47	`01`	`1`		`@0 04-0316775`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of virology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) causes severe pneumonia with a fatal outcome in approximately 10% of patients. SARS-CoV is not closely related to other coronaviruses but shares a similar genome organization. Entry of coronaviruses into target cells is mediated by the viral S protein. We functionally analyzed SARS-CoV S using pseudotyped lentiviral particles (pseudotypes). The SARS-CoV S protein was found to be expressed at the cell surface upon transient transfection. Coexpression of SARS-CoV S with human immunodeficiency virus-based reporter constructs yielded viruses that were infectious for a range of cell lines. Most notably, viral pseudotypes harboring SARS-CoV S infected hepatoma cell lines but not T- and B-cell lines. Infection of the hepatoma cell line Huh-7 was also observed with replication-competent SARS-CoV, indicating that hepatocytes might be targeted by SARS-CoV in vivo. Inhibition of vacuolar acidification impaired infection by SARS-CoV S-bearing pseudotypes, indicating that S-mediated entry requires low pH. Finally, infection by SARS-CoV S pseudotypes but not by vesicular stomatitis virus G pseudotypes was efficiently inhibited by a rabbit serum raised against SARS-CoV particles and by sera from SARS patients, demonstrating that SARS-CoV S is a target for neutralizing antibodies and that such antibodies are generated in SARS-CoV-infected patients. Our results show that viral pseudotyping can be employed for the analysis of SARS-CoV S function. Moreover, we provide evidence that SARS-CoV infection might not be limited to lung tissue and can be inhibited by the humoral immune response in infected patients.
C02	`01`	`X`		`@0 002A05C10`
C02	`02`	`X`		`@0 002B04`
C03	`01`	`X`	`FRE`	`@0 Coronavirus @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 Coronavirus @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 Coronavirus @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 Homme @5 02`
C03	`02`	`X`	`ENG`	`@0 Human @5 02`
C03	`02`	`X`	`SPA`	`@0 Hombre @5 02`
C03	`03`	`X`	`FRE`	`@0 Vitronectine @5 05`
C03	`03`	`X`	`ENG`	`@0 Vitronectin @5 05`
C03	`03`	`X`	`SPA`	`@0 Vitronectina @5 05`
C03	`04`	`X`	`FRE`	`@0 Protéine @5 06`
C03	`04`	`X`	`ENG`	`@0 Protein @5 06`
C03	`04`	`X`	`SPA`	`@0 Proteína @5 06`
C03	`05`	`X`	`FRE`	`@0 Lignée cellulaire @5 07`
C03	`05`	`X`	`ENG`	`@0 Cell line @5 07`
C03	`05`	`X`	`SPA`	`@0 Línea celular @5 07`
C03	`06`	`X`	`FRE`	`@0 Cellule cible @5 08`
C03	`06`	`X`	`ENG`	`@0 Target cell @5 08`
C03	`06`	`X`	`SPA`	`@0 Célula blanco @5 08`
C03	`07`	`X`	`FRE`	`@0 Anticorps neutralisant @5 09`
C03	`07`	`X`	`ENG`	`@0 Neutralizing antibody @5 09`
C03	`07`	`X`	`SPA`	`@0 anticuerpo neutralizante @5 09`
C03	`08`	`X`	`FRE`	`@0 Neutralisation @5 10`
C03	`08`	`X`	`ENG`	`@0 Neutralization @5 10`
C03	`08`	`X`	`SPA`	`@0 Neutralización @5 10`
C03	`09`	`X`	`FRE`	`@0 Infection @2 NM @5 11`
C03	`09`	`X`	`ENG`	`@0 Infection @2 NM @5 11`
C03	`09`	`X`	`SPA`	`@0 Infección @2 NM @5 11`
C03	`10`	`X`	`FRE`	`@0 Microbiologie @5 12`
C03	`10`	`X`	`ENG`	`@0 Microbiology @5 12`
C03	`10`	`X`	`SPA`	`@0 Microbiología @5 12`
C03	`11`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 14`
C03	`11`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 14`
C03	`11`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 14`
C03	`12`	`X`	`FRE`	`@0 Carcinome hépatocellulaire @5 15`
C03	`12`	`X`	`ENG`	`@0 Hepatocellular carcinoma @5 15`
C03	`12`	`X`	`SPA`	`@0 Carcinoma hepatocelular @5 15`
C03	`13`	`X`	`FRE`	`@0 Virologie @5 67`
C03	`13`	`X`	`ENG`	`@0 Virology @5 67`
C03	`13`	`X`	`SPA`	`@0 Virología @5 67`
C07	`01`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virose @2 NM`
C07	`04`	`X`	`ENG`	`@0 Viral disease @2 NM`
C07	`04`	`X`	`SPA`	`@0 Virosis @2 NM`
C07	`05`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 19`
C07	`05`	`X`	`ENG`	`@0 Respiratory disease @5 19`
C07	`05`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 19`
C07	`06`	`X`	`FRE`	`@0 Poumon pathologie @5 20`
C07	`06`	`X`	`ENG`	`@0 Lung disease @5 20`
C07	`06`	`X`	`SPA`	`@0 Pulmón patología @5 20`
C07	`07`	`X`	`FRE`	`@0 Appareil digestif pathologie @5 22`
C07	`07`	`X`	`ENG`	`@0 Digestive diseases @5 22`
C07	`07`	`X`	`SPA`	`@0 Aparato digestivo patología @5 22`
C07	`08`	`X`	`FRE`	`@0 Foie pathologie @5 23`
C07	`08`	`X`	`ENG`	`@0 Hepatic disease @5 23`
C07	`08`	`X`	`SPA`	`@0 Hígado patología @5 23`
C07	`09`	`X`	`FRE`	`@0 Tumeur maligne @5 24`
C07	`09`	`X`	`ENG`	`@0 Malignant tumor @5 24`
C07	`09`	`X`	`SPA`	`@0 Tumor maligno @5 24`
N21				`@1 187`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 04-0316775 INIST
ET :	S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients
AU :	HOFMANN (Heike); HATTERMANN (Kim); MARZI (Andrea); GRAMBERG (Thomas); GEIER (Martina); KRUMBIEGEL (Mandy); KUATE (Seraphin); ÜBERLA (Klaus); NIEDRIG (Matthias); PÖHLMANN (Stefan)
AF :	Institute for Clinical and Molecular Virology, University Erlangen-Nürnberg/91054 Erlangen/Allemagne (1 aut., 3 aut., 4 aut., 5 aut., 6 aut., 10 aut.); Nikolaus-Fiebiger-Center, University Erlangen-Nürnberg/91054 Erlangen/Allemagne (1 aut., 3 aut., 4 aut., 5 aut., 6 aut., 10 aut.); Robert Koch Institute/13353 Berlin/Allemagne (2 aut., 9 aut.); Department for Molecular and Medical Virology, Ruhr University Bochum/44801 Bochum/Allemagne (7 aut., 8 aut.)
DT :	Publication en série; Niveau analytique
SO :	Journal of virology; ISSN 0022-538X; Etats-Unis; Da. 2004; Vol. 78; No. 12; Pp. 6134-6142; Bibl. 75 ref.
LA :	Anglais
EA :	The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) causes severe pneumonia with a fatal outcome in approximately 10% of patients. SARS-CoV is not closely related to other coronaviruses but shares a similar genome organization. Entry of coronaviruses into target cells is mediated by the viral S protein. We functionally analyzed SARS-CoV S using pseudotyped lentiviral particles (pseudotypes). The SARS-CoV S protein was found to be expressed at the cell surface upon transient transfection. Coexpression of SARS-CoV S with human immunodeficiency virus-based reporter constructs yielded viruses that were infectious for a range of cell lines. Most notably, viral pseudotypes harboring SARS-CoV S infected hepatoma cell lines but not T- and B-cell lines. Infection of the hepatoma cell line Huh-7 was also observed with replication-competent SARS-CoV, indicating that hepatocytes might be targeted by SARS-CoV in vivo. Inhibition of vacuolar acidification impaired infection by SARS-CoV S-bearing pseudotypes, indicating that S-mediated entry requires low pH. Finally, infection by SARS-CoV S pseudotypes but not by vesicular stomatitis virus G pseudotypes was efficiently inhibited by a rabbit serum raised against SARS-CoV particles and by sera from SARS patients, demonstrating that SARS-CoV S is a target for neutralizing antibodies and that such antibodies are generated in SARS-CoV-infected patients. Our results show that viral pseudotyping can be employed for the analysis of SARS-CoV S function. Moreover, we provide evidence that SARS-CoV infection might not be limited to lung tissue and can be inhibited by the humoral immune response in infected patients.
CC :	002A05C10; 002B04
FD :	Coronavirus; Homme; Vitronectine; Protéine; Lignée cellulaire; Cellule cible; Anticorps neutralisant; Neutralisation; Infection; Microbiologie; Syndrome respiratoire aigu sévère; Carcinome hépatocellulaire; Virologie
FG :	Coronaviridae; Nidovirales; Virus; Virose; Appareil respiratoire pathologie; Poumon pathologie; Appareil digestif pathologie; Foie pathologie; Tumeur maligne
ED :	Coronavirus; Human; Vitronectin; Protein; Cell line; Target cell; Neutralizing antibody; Neutralization; Infection; Microbiology; Severe acute respiratory syndrome; Hepatocellular carcinoma; Virology
EG :	Coronaviridae; Nidovirales; Virus; Viral disease; Respiratory disease; Lung disease; Digestive diseases; Hepatic disease; Malignant tumor
SD :	Coronavirus; Hombre; Vitronectina; Proteína; Línea celular; Célula blanco; anticuerpo neutralizante; Neutralización; Infección; Microbiología; Síndrome respiratorio agudo severo; Carcinoma hepatocelular; Virología
LO :	INIST-13592.354000112010850060
ID :	04-0316775

Links to Exploration step

Pascal:04-0316775

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients</title>
<author><name sortKey="Hofmann, Heike" sort="Hofmann, Heike" uniqKey="Hofmann H" first="Heike" last="Hofmann">Heike Hofmann</name>
<affiliation><inist:fA14 i1="01"><s1>Institute for Clinical and Molecular Virology, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Nikolaus-Fiebiger-Center, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hattermann, Kim" sort="Hattermann, Kim" uniqKey="Hattermann K" first="Kim" last="Hattermann">Kim Hattermann</name>
<affiliation><inist:fA14 i1="03"><s1>Robert Koch Institute</s1>
<s2>13353 Berlin</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marzi, Andrea" sort="Marzi, Andrea" uniqKey="Marzi A" first="Andrea" last="Marzi">Andrea Marzi</name>
<affiliation><inist:fA14 i1="01"><s1>Institute for Clinical and Molecular Virology, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Nikolaus-Fiebiger-Center, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gramberg, Thomas" sort="Gramberg, Thomas" uniqKey="Gramberg T" first="Thomas" last="Gramberg">Thomas Gramberg</name>
<affiliation><inist:fA14 i1="01"><s1>Institute for Clinical and Molecular Virology, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Nikolaus-Fiebiger-Center, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Geier, Martina" sort="Geier, Martina" uniqKey="Geier M" first="Martina" last="Geier">Martina Geier</name>
<affiliation><inist:fA14 i1="01"><s1>Institute for Clinical and Molecular Virology, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Nikolaus-Fiebiger-Center, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Krumbiegel, Mandy" sort="Krumbiegel, Mandy" uniqKey="Krumbiegel M" first="Mandy" last="Krumbiegel">Mandy Krumbiegel</name>
<affiliation><inist:fA14 i1="01"><s1>Institute for Clinical and Molecular Virology, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Nikolaus-Fiebiger-Center, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kuate, Seraphin" sort="Kuate, Seraphin" uniqKey="Kuate S" first="Seraphin" last="Kuate">Seraphin Kuate</name>
<affiliation><inist:fA14 i1="04"><s1>Department for Molecular and Medical Virology, Ruhr University Bochum</s1>
<s2>44801 Bochum</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Uberla, Klaus" sort="Uberla, Klaus" uniqKey="Uberla K" first="Klaus" last="Überla">Klaus Überla</name>
<affiliation><inist:fA14 i1="04"><s1>Department for Molecular and Medical Virology, Ruhr University Bochum</s1>
<s2>44801 Bochum</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Niedrig, Matthias" sort="Niedrig, Matthias" uniqKey="Niedrig M" first="Matthias" last="Niedrig">Matthias Niedrig</name>
<affiliation><inist:fA14 i1="03"><s1>Robert Koch Institute</s1>
<s2>13353 Berlin</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pohlmann, Stefan" sort="Pohlmann, Stefan" uniqKey="Pohlmann S" first="Stefan" last="Pöhlmann">Stefan Pöhlmann</name>
<affiliation><inist:fA14 i1="01"><s1>Institute for Clinical and Molecular Virology, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Nikolaus-Fiebiger-Center, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0316775</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0316775 INIST</idno>
<idno type="RBID">Pascal:04-0316775</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000876</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients</title>
<author><name sortKey="Hofmann, Heike" sort="Hofmann, Heike" uniqKey="Hofmann H" first="Heike" last="Hofmann">Heike Hofmann</name>
<affiliation><inist:fA14 i1="01"><s1>Institute for Clinical and Molecular Virology, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Nikolaus-Fiebiger-Center, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hattermann, Kim" sort="Hattermann, Kim" uniqKey="Hattermann K" first="Kim" last="Hattermann">Kim Hattermann</name>
<affiliation><inist:fA14 i1="03"><s1>Robert Koch Institute</s1>
<s2>13353 Berlin</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marzi, Andrea" sort="Marzi, Andrea" uniqKey="Marzi A" first="Andrea" last="Marzi">Andrea Marzi</name>
<affiliation><inist:fA14 i1="01"><s1>Institute for Clinical and Molecular Virology, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Nikolaus-Fiebiger-Center, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gramberg, Thomas" sort="Gramberg, Thomas" uniqKey="Gramberg T" first="Thomas" last="Gramberg">Thomas Gramberg</name>
<affiliation><inist:fA14 i1="01"><s1>Institute for Clinical and Molecular Virology, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Nikolaus-Fiebiger-Center, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Geier, Martina" sort="Geier, Martina" uniqKey="Geier M" first="Martina" last="Geier">Martina Geier</name>
<affiliation><inist:fA14 i1="01"><s1>Institute for Clinical and Molecular Virology, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Nikolaus-Fiebiger-Center, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Krumbiegel, Mandy" sort="Krumbiegel, Mandy" uniqKey="Krumbiegel M" first="Mandy" last="Krumbiegel">Mandy Krumbiegel</name>
<affiliation><inist:fA14 i1="01"><s1>Institute for Clinical and Molecular Virology, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Nikolaus-Fiebiger-Center, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kuate, Seraphin" sort="Kuate, Seraphin" uniqKey="Kuate S" first="Seraphin" last="Kuate">Seraphin Kuate</name>
<affiliation><inist:fA14 i1="04"><s1>Department for Molecular and Medical Virology, Ruhr University Bochum</s1>
<s2>44801 Bochum</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Uberla, Klaus" sort="Uberla, Klaus" uniqKey="Uberla K" first="Klaus" last="Überla">Klaus Überla</name>
<affiliation><inist:fA14 i1="04"><s1>Department for Molecular and Medical Virology, Ruhr University Bochum</s1>
<s2>44801 Bochum</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Niedrig, Matthias" sort="Niedrig, Matthias" uniqKey="Niedrig M" first="Matthias" last="Niedrig">Matthias Niedrig</name>
<affiliation><inist:fA14 i1="03"><s1>Robert Koch Institute</s1>
<s2>13353 Berlin</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pohlmann, Stefan" sort="Pohlmann, Stefan" uniqKey="Pohlmann S" first="Stefan" last="Pöhlmann">Stefan Pöhlmann</name>
<affiliation><inist:fA14 i1="01"><s1>Institute for Clinical and Molecular Virology, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Nikolaus-Fiebiger-Center, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of virology</title>
<title level="j" type="abbreviated">J. virol.</title>
<idno type="ISSN">0022-538X</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of virology</title>
<title level="j" type="abbreviated">J. virol.</title>
<idno type="ISSN">0022-538X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cell line</term>
<term>Coronavirus</term>
<term>Hepatocellular carcinoma</term>
<term>Human</term>
<term>Infection</term>
<term>Microbiology</term>
<term>Neutralization</term>
<term>Neutralizing antibody</term>
<term>Protein</term>
<term>Severe acute respiratory syndrome</term>
<term>Target cell</term>
<term>Virology</term>
<term>Vitronectin</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Coronavirus</term>
<term>Homme</term>
<term>Vitronectine</term>
<term>Protéine</term>
<term>Lignée cellulaire</term>
<term>Cellule cible</term>
<term>Anticorps neutralisant</term>
<term>Neutralisation</term>
<term>Infection</term>
<term>Microbiologie</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Carcinome hépatocellulaire</term>
<term>Virologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) causes severe pneumonia with a fatal outcome in approximately 10% of patients. SARS-CoV is not closely related to other coronaviruses but shares a similar genome organization. Entry of coronaviruses into target cells is mediated by the viral S protein. We functionally analyzed SARS-CoV S using pseudotyped lentiviral particles (pseudotypes). The SARS-CoV S protein was found to be expressed at the cell surface upon transient transfection. Coexpression of SARS-CoV S with human immunodeficiency virus-based reporter constructs yielded viruses that were infectious for a range of cell lines. Most notably, viral pseudotypes harboring SARS-CoV S infected hepatoma cell lines but not T- and B-cell lines. Infection of the hepatoma cell line Huh-7 was also observed with replication-competent SARS-CoV, indicating that hepatocytes might be targeted by SARS-CoV in vivo. Inhibition of vacuolar acidification impaired infection by SARS-CoV S-bearing pseudotypes, indicating that S-mediated entry requires low pH. Finally, infection by SARS-CoV S pseudotypes but not by vesicular stomatitis virus G pseudotypes was efficiently inhibited by a rabbit serum raised against SARS-CoV particles and by sera from SARS patients, demonstrating that SARS-CoV S is a target for neutralizing antibodies and that such antibodies are generated in SARS-CoV-infected patients. Our results show that viral pseudotyping can be employed for the analysis of SARS-CoV S function. Moreover, we provide evidence that SARS-CoV infection might not be limited to lung tissue and can be inhibited by the humoral immune response in infected patients.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-538X</s0>
</fA01>
<fA03 i2="1"><s0>J. virol.</s0>
</fA03>
<fA05><s2>78</s2>
</fA05>
<fA06><s2>12</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HOFMANN (Heike)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>HATTERMANN (Kim)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MARZI (Andrea)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>GRAMBERG (Thomas)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GEIER (Martina)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>KRUMBIEGEL (Mandy)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>KUATE (Seraphin)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>ÜBERLA (Klaus)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>NIEDRIG (Matthias)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>PÖHLMANN (Stefan)</s1>
</fA11>
<fA14 i1="01"><s1>Institute for Clinical and Molecular Virology, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Nikolaus-Fiebiger-Center, University Erlangen-Nürnberg</s1>
<s2>91054 Erlangen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Robert Koch Institute</s1>
<s2>13353 Berlin</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department for Molecular and Medical Virology, Ruhr University Bochum</s1>
<s2>44801 Bochum</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>6134-6142</s1>
</fA20>
<fA21><s1>2004</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>13592</s2>
<s5>354000112010850060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>75 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0316775</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of virology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) causes severe pneumonia with a fatal outcome in approximately 10% of patients. SARS-CoV is not closely related to other coronaviruses but shares a similar genome organization. Entry of coronaviruses into target cells is mediated by the viral S protein. We functionally analyzed SARS-CoV S using pseudotyped lentiviral particles (pseudotypes). The SARS-CoV S protein was found to be expressed at the cell surface upon transient transfection. Coexpression of SARS-CoV S with human immunodeficiency virus-based reporter constructs yielded viruses that were infectious for a range of cell lines. Most notably, viral pseudotypes harboring SARS-CoV S infected hepatoma cell lines but not T- and B-cell lines. Infection of the hepatoma cell line Huh-7 was also observed with replication-competent SARS-CoV, indicating that hepatocytes might be targeted by SARS-CoV in vivo. Inhibition of vacuolar acidification impaired infection by SARS-CoV S-bearing pseudotypes, indicating that S-mediated entry requires low pH. Finally, infection by SARS-CoV S pseudotypes but not by vesicular stomatitis virus G pseudotypes was efficiently inhibited by a rabbit serum raised against SARS-CoV particles and by sera from SARS patients, demonstrating that SARS-CoV S is a target for neutralizing antibodies and that such antibodies are generated in SARS-CoV-infected patients. Our results show that viral pseudotyping can be employed for the analysis of SARS-CoV S function. Moreover, we provide evidence that SARS-CoV infection might not be limited to lung tissue and can be inhibited by the humoral immune response in infected patients.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C10</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B04</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Homme</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Human</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Hombre</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Vitronectine</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Vitronectin</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Vitronectina</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Protéine</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Protein</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Proteína</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Lignée cellulaire</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Cell line</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Línea celular</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Cellule cible</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Target cell</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Célula blanco</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Anticorps neutralisant</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Neutralizing antibody</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>anticuerpo neutralizante</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Neutralisation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Neutralization</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Neutralización</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Infection</s0>
<s2>NM</s2>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Infection</s0>
<s2>NM</s2>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Infección</s0>
<s2>NM</s2>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Microbiologie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Microbiology</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Microbiología</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Carcinome hépatocellulaire</s0>
<s5>15</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Hepatocellular carcinoma</s0>
<s5>15</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Carcinoma hepatocelular</s0>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Virologie</s0>
<s5>67</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Virology</s0>
<s5>67</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Virología</s0>
<s5>67</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virose</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Viral disease</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virosis</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>19</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>19</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>19</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>20</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>20</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>20</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Appareil digestif pathologie</s0>
<s5>22</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Digestive diseases</s0>
<s5>22</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Aparato digestivo patología</s0>
<s5>22</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Foie pathologie</s0>
<s5>23</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Hepatic disease</s0>
<s5>23</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Hígado patología</s0>
<s5>23</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s5>24</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s5>24</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s5>24</s5>
</fC07>
<fN21><s1>187</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 04-0316775 INIST</NO>
<ET>S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients</ET>
<AU>HOFMANN (Heike); HATTERMANN (Kim); MARZI (Andrea); GRAMBERG (Thomas); GEIER (Martina); KRUMBIEGEL (Mandy); KUATE (Seraphin); ÜBERLA (Klaus); NIEDRIG (Matthias); PÖHLMANN (Stefan)</AU>
<AF>Institute for Clinical and Molecular Virology, University Erlangen-Nürnberg/91054 Erlangen/Allemagne (1 aut., 3 aut., 4 aut., 5 aut., 6 aut., 10 aut.); Nikolaus-Fiebiger-Center, University Erlangen-Nürnberg/91054 Erlangen/Allemagne (1 aut., 3 aut., 4 aut., 5 aut., 6 aut., 10 aut.); Robert Koch Institute/13353 Berlin/Allemagne (2 aut., 9 aut.); Department for Molecular and Medical Virology, Ruhr University Bochum/44801 Bochum/Allemagne (7 aut., 8 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of virology; ISSN 0022-538X; Etats-Unis; Da. 2004; Vol. 78; No. 12; Pp. 6134-6142; Bibl. 75 ref.</SO>
<LA>Anglais</LA>
<EA>The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) causes severe pneumonia with a fatal outcome in approximately 10% of patients. SARS-CoV is not closely related to other coronaviruses but shares a similar genome organization. Entry of coronaviruses into target cells is mediated by the viral S protein. We functionally analyzed SARS-CoV S using pseudotyped lentiviral particles (pseudotypes). The SARS-CoV S protein was found to be expressed at the cell surface upon transient transfection. Coexpression of SARS-CoV S with human immunodeficiency virus-based reporter constructs yielded viruses that were infectious for a range of cell lines. Most notably, viral pseudotypes harboring SARS-CoV S infected hepatoma cell lines but not T- and B-cell lines. Infection of the hepatoma cell line Huh-7 was also observed with replication-competent SARS-CoV, indicating that hepatocytes might be targeted by SARS-CoV in vivo. Inhibition of vacuolar acidification impaired infection by SARS-CoV S-bearing pseudotypes, indicating that S-mediated entry requires low pH. Finally, infection by SARS-CoV S pseudotypes but not by vesicular stomatitis virus G pseudotypes was efficiently inhibited by a rabbit serum raised against SARS-CoV particles and by sera from SARS patients, demonstrating that SARS-CoV S is a target for neutralizing antibodies and that such antibodies are generated in SARS-CoV-infected patients. Our results show that viral pseudotyping can be employed for the analysis of SARS-CoV S function. Moreover, we provide evidence that SARS-CoV infection might not be limited to lung tissue and can be inhibited by the humoral immune response in infected patients.</EA>
<CC>002A05C10; 002B04</CC>
<FD>Coronavirus; Homme; Vitronectine; Protéine; Lignée cellulaire; Cellule cible; Anticorps neutralisant; Neutralisation; Infection; Microbiologie; Syndrome respiratoire aigu sévère; Carcinome hépatocellulaire; Virologie</FD>
<FG>Coronaviridae; Nidovirales; Virus; Virose; Appareil respiratoire pathologie; Poumon pathologie; Appareil digestif pathologie; Foie pathologie; Tumeur maligne</FG>
<ED>Coronavirus; Human; Vitronectin; Protein; Cell line; Target cell; Neutralizing antibody; Neutralization; Infection; Microbiology; Severe acute respiratory syndrome; Hepatocellular carcinoma; Virology</ED>
<EG>Coronaviridae; Nidovirales; Virus; Viral disease; Respiratory disease; Lung disease; Digestive diseases; Hepatic disease; Malignant tumor</EG>
<SD>Coronavirus; Hombre; Vitronectina; Proteína; Línea celular; Célula blanco; anticuerpo neutralizante; Neutralización; Infección; Microbiología; Síndrome respiratorio agudo severo; Carcinoma hepatocelular; Virología</SD>
<LO>INIST-13592.354000112010850060</LO>
<ID>04-0316775</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000876 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000876 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:04-0316775
   |texte=   S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients

S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri